GT Biopharma, Inc.
GTBP
$2.35
$0.062.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.83M | 2.30M | 2.12M | 2.31M | 1.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.76M | 3.60M | 3.91M | 3.09M | 3.17M |
| Operating Income | -3.76M | -3.60M | -3.91M | -3.09M | -3.17M |
| Income Before Tax | -3.78M | -3.41M | -3.71M | -2.27M | -2.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.78M | -3.41M | -3.71M | -2.27M | -2.96M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.78M | -3.41M | -3.71M | -2.27M | -2.96M |
| EBIT | -3.76M | -3.60M | -3.91M | -3.09M | -3.17M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.67 | -1.53 | -2.17 | -1.64 | -2.14 |
| Normalized Basic EPS | -1.04 | -0.95 | -1.35 | -1.02 | -1.34 |
| EPS Diluted | -1.67 | -1.53 | -2.17 | -1.64 | -2.14 |
| Normalized Diluted EPS | -1.04 | -0.95 | -1.35 | -1.02 | -1.34 |
| Average Basic Shares Outstanding | 2.26M | 2.23M | 1.71M | 1.38M | 1.38M |
| Average Diluted Shares Outstanding | 2.26M | 2.23M | 1.71M | 1.38M | 1.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |